General Biologicals Corp. (GBC)

General Biologicals Corp. (GBC) is an industry-leading in-vitro diagnostic device manufacturer founded in 1984, with headquarters in Taiwan. GBC is certified with IVD Class III, GMP, and ISO 13485:2003. The company has developed a wide spectrum of technology platforms for various diagnostic products, including Raw Materials (antibody & antigen), RIA, ELISA, POCT, and RT-PCR. GBC also possesses its own intensive sequential vertical technology platform of hybridoma techniques. Specializing in liver diagnostics, GBC offers a full turnkey liver diagnostic platform, addressing inflammation, liver fibrosis (BioFibroScoretm), Cirrhosis, and HCC (AFP). Furthermore, through its subsidiary, CurieMed Laboratory, GBC is offering the Liver20 service, encompassing 20 tests related to the liver in Taiwan. With its slogan "An innovated IVD manufacturer making quality products for everyone," GBC continues to make significant strides in the Health Care, Manufacturing, and Pharmaceutical industries. Currently, there is no public information available regarding GBC's last investment.